CONMED

CNMD

市值 US$14億

LARGO, Fla.--(BUSINESS WIRE)--CONMED Corporation (NYSE: CNMD) today announced that it will report financial results for the third quarter 2026 after the market close on Wednesday, October 28, 2026. The Company's management will host a conference call at 4:30 p.m. ET that same day to discuss the results. To participate in the conference call via live webcast, please click here. To participate via telephone, please click here to pre-register and obtain the dial-in number and passcode. This confer.

In Q2 2026, the Harbor SMID Cap Value ETF returned 22.76%, outperforming its benchmark, the Russell 2500 Value Index, which returned 18.50%. Contributing to performance was Albany International, whose shares gained 43% during the quarter following better-than-expected operating results and continued strength in its aerospace and defense businesses. Another contributor to performance was BorgWarner, whose shares gained 23% during the quarter following better-than-expected first quarter results and growing investor optimism around the company's long-term growth opportunities.

CONMED's BioBrace and AirSeal platforms, robotic growth and easing supply bottlenecks support its long-term outlook despite tariff headwinds.

The Harbor Small Cap Value Fund returned 21.09%, outperforming the Russell 2000 Value Index, which returned 17.19%, net of fees, during Q2 2026. Contributing to performance was Albany International Corp., a manufacturer of specialized engineered materials serving the paper production and aerospace industries. We made no purchases or sales in the second quarter of 2026.

Conmed (CNMD) reported earnings 30 days ago. What's next for the stock?

LARGO, Fla.--(BUSINESS WIRE)--CONMED Corporation (NYSE: CNMD) today announced its participation in the Wells Fargo 21st Annual Healthcare Conference, which is being held September 8-10, 2026 at the Encore Boston Harbor in Everett, MA. Management will participate in a fireside chat on Wednesday, September 9th at 1:30 p.m. Eastern Time. A live audio webcast of the fireside chat will be accessible under the “Events” section of the company's investor relations website: https://www.conmed.com/en/inv.

Conmed's headline growth appeared flat at $343 million in the last quarter, but organic growth actually increased by 6%, with the leading segment being the orthopedic surgery business. Growth was offset by the divestiture of the GI business; as a result, growth metrics look poor with a quant rating of F and below the sector growth. When I adjust for organic growth, impressive profitability, and a buyback story, Conmed stock looks highly undervalued below the sector multiple. and I am rating it a buy.

CNMD's 16% monthly rally is backed by stronger growth, margin gains and raised earnings guidance, but cash-flow and execution risks remain.

CONMED raised its 2026 adjusted EPS outlook after a strong second quarter, but slower organic growth and higher financing costs keep the setup mixed.

CNMD's low valuation and improved earnings outlook strengthen its appeal, but cash-flow pressure and execution risks keep the buy case measured.